Oxidative Stress–Driven Ferroptosis in Neurodegenerative Diseases: Biochemical Mechanisms, Molecular Pathways, and Therapeutic Perspectives — A Review
Keywords:
Oxidative stress, Ferroptosis, Neurodegeneration, GPX4, Nrf2, Lipid peroxidation, Mitochondria, Iron metabolismAbstract
Neurodegenerative diseases are characterized by progressive neuronal dysfunction and chronic loss of neuronal populations, accompanied by alterations in synaptic networks and selective vulnerability of neural circuits. Redox imbalance is a common biochemical hallmark linking these disorders, in which excessive reactive oxygen species (ROS), impaired antioxidant defenses, mitochondrial dysfunction, and abnormal iron metabolism collectively damage lipids, proteins, and nucleic acids. Ferroptosis is a recently identified iron-dependent form of regulated cell death driven by phospholipid peroxidation and insufficient detoxification by glutathione peroxidase 4 (GPX4). Unlike apoptosis or necroptosis, ferroptosis is characterized by redox-active iron overload, glutathione depletion, impaired lipid peroxide repair, and catastrophic membrane damage. These mechanisms are particularly relevant in neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple sclerosis, where iron accumulation, mitochondrial ROS production, lipid peroxidation, neuroinflammation, and protein aggregation interact to promote disease progression. This review summarizes recent evidence on the roles of oxidative stress and ferroptosis in neurodegeneration, with emphasis on the SLC7A11/GSH/GPX4 pathway, Nrf2-mediated antioxidant signaling, ACSL4-dependent lipid remodeling, the FSP1–CoQ10 defense system, ferritinophagy, and mitochondrial redox dysfunction. It also discusses emerging therapeutic strategies, including iron chelation, radical-trapping antioxidants, Nrf2 activation, selenium and glutathione supplementation, ferroptosis-modulating agents, mitochondrial-targeted therapies, and lifestyle-based redox modulation. Although ferroptosis-targeted therapies show considerable promise, their clinical translation requires validated biomarkers, blood–brain barrier-permeable agents, appropriate disease-stage stratification, and careful preservation of physiological redox signaling.